Based on the hypothesis that an enhanced dopaminergic activity in the basal ganglia may play a major role in tardive dyskinesia, the clinical efficacy of two dopamine-blocking agents, haloperidol (Haldol) and thiopropazate dihydrochloride (Dartal), for the short-term treatment of tardive dyskinesia was studied on 20 patients for four weeks. Both drugs were shown to have marked antidyskinetic effects in over a half of the patients. Improvements of dyskinesia were not always accompanied by development of reversible extrapyramidal symptoms. These results, together with the findings obtained in the previous study, appear to support the above-mentioned hypothesis, and suggest another approach to the symptomatic control of tardive dyskinesia through neurochemical regulation, although the clinical practicability of these drug regimens over a longer period of time is not established and needs further investigation.
Kazamatsuri H, Chien C, Cole JO. Treatment of Tardive Dyskinesia: II. Short-Term Efficacy of Dopamine-Blocking Agents Haloperidol and Thiopropazate. Arch Gen Psychiatry. 1972;27(1):100–103. doi:10.1001/archpsyc.1972.01750250086012
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: